Cardiff Oncology, Inc. (NasdaqCM: CRDF)
Health Care · Biotechnology · US
$1.02
-6.02% today · -51.1% 1Y
Cardiff Oncology, Inc. (NasdaqCM: CRDF) operates in the Biotechnology industry within the Health Care sector. The company is valued at $84.02M and employs 31 people.
Over the last twelve months the share price has lost 51.1%, trading between 0.76 and 3.31.
Tweenvest scores Cardiff Oncology, Inc. across four factors: quality 37/100, value 47/100, growth 61/100. Its strongest factor is growth.
CRDF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $84.02M
- Revenue (TTM)
- $508.00K
- P/E
- —
- EPS
- -0.59
- Dividend yield
- —
- Beta (5Y)
- 1.42
- 52-week high
- $3.31
- 52-week low
- $0.76
- Avg volume (3M)
- —
- Shares outstanding
- 77.80M
- Employees
- 31
- Next earnings
- —
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
- ISIN
- US14147L1089
- Founded
- 1999
- Listed since
- Jul 27, 2004
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ReproCELL IncorporatedTSE: 4978 | $85.24M | ¥130.00 | -1.52% |
| ProMIS Neurosciences, Inc.NasdaqCM: PMN | $84.74M | $9.78 | +3.44% |
| BIOTON S.A.WSE: BIO | $84.38M | zł3.80 | -1.30% |
| Allied Biotech CorporationTPEX: 1780 | $84.09M | NT$24.65 | -2.76% |
| 3D Global Biotech Inc.TPEX: 6808 | $83.18M | NT$34.55 | +1.62% |
| Acrivon Therapeutics, Inc.NasdaqGM: ACRV | $81.85M | $1.83 | -4.19% |
| Prestige Biologics Co., Ltd.KOSDAQ: A334970 | $81.43M | ₩1,408.00 | -1.81% |
| BIONET Therapeutics Corp.TPEX: 7808 | $81.00M | NT$37.00 | -8.64% |
Figures last refreshed Oct 11, 2026.